公开(公告)号：US20240358734A1

公开(公告)日：2024-10-31

申请号：US18647744

申请日：2024-04-26

申请人： The Hong Kong University of Science and Technology ,  Southern Marine Science and Engineering Guangdong Laboratory (Guangzhou)

发明人： Peiyuan QIAN ,  Pingbo HUANG ,  Wenkang YE ,  Sin Tung LUI ,  Qirui ZHAO ,  Aifang CHENG

IPC分类号： A61K31/7048 ,  A61K31/55 ,  A61K47/20 ,  A61P29/00

CPC分类号： A61K31/7048 ,  A61K31/55 ,  A61K47/20 ,  A61P29/00

摘要： The subject invention pertains to hexacyclic xanthones isolated from marine bacteria. These chrexanthomycins are effective TRPV1 inhibitors that are effective as analgesics.

公开(公告)号：US20240343807A1

公开(公告)日：2024-10-17

申请号：US18292655

申请日：2022-08-05

申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.

发明人： Xiquan ZHANG ,  Xunqiang WANG ,  Ding YU

IPC分类号： C07K16/28 ,  A61K31/4709 ,  A61K31/555 ,  A61K31/7048 ,  A61K39/00 ,  A61P35/00

CPC分类号： C07K16/2827 ,  A61K31/4709 ,  A61K31/555 ,  A61K31/7048 ,  A61P35/00 ,  A61K2039/505 ,  A61K2039/545

摘要： Provided is a pharmaceutical composition for treating small cell lung cancer, which comprises an anti-PD-L1 antibody, anlotinib or a pharmaceutically acceptable salt thereof, and a chemotherapeutic drug. Further provided is the use of the pharmaceutical composition or a kit containing the anti-PD-L1 antibody, anlotinib or a pharmaceutically acceptable salt thereof and the chemotherapeutic drug in the preparation of a drug for treating small cell lung cancer. Further provided is a method for treating small cell lung cancer, comprising administering to a patient in need thereof a therapeutically effective amount of the anti-PD-L1 antibody, anlotinib or a pharmaceutically acceptable salt thereof, and the chemotherapeutic drug.

公开(公告)号：US20240335514A1

公开(公告)日：2024-10-10

申请号：US18746567

申请日：2024-06-18

申请人： Boehringer Ingelheim International GmbH

发明人： Rolf GREMPLER ,  Odd-Erik JOHANSEN ,  Thomas KLEIN ,  Gerd Roland LUIPPOLD ,  Michael MARK

IPC分类号： A61K38/28 ,  A61K31/341 ,  A61K31/7048 ,  A61K45/06

CPC分类号： A61K38/28 ,  A61K31/341 ,  A61K31/7048 ,  A61K45/06

摘要： The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor and an insulin which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions

公开(公告)号：US12109201B2

公开(公告)日：2024-10-08

申请号：US17843028

申请日：2022-06-17

申请人： Ovid Therapeutics, Inc.

发明人： Matthew During

IPC分类号： A61K31/437 ,  A61K9/00 ,  A61K31/165 ,  A61K31/19 ,  A61K31/195 ,  A61K31/197 ,  A61K31/27 ,  A61K31/325 ,  A61K31/36 ,  A61K31/4015 ,  A61K31/4166 ,  A61K31/4192 ,  A61K31/423 ,  A61K31/433 ,  A61K31/44 ,  A61K31/444 ,  A61K31/4535 ,  A61K31/513 ,  A61K31/515 ,  A61K31/53 ,  A61K31/55 ,  A61K31/5513 ,  A61K31/5517 ,  A61K31/57 ,  A61K31/7048 ,  A61K45/06

CPC分类号： A61K31/437 ,  A61K9/0019 ,  A61K31/165 ,  A61K31/19 ,  A61K31/195 ,  A61K31/197 ,  A61K31/27 ,  A61K31/325 ,  A61K31/36 ,  A61K31/4015 ,  A61K31/4166 ,  A61K31/4192 ,  A61K31/423 ,  A61K31/433 ,  A61K31/44 ,  A61K31/444 ,  A61K31/4535 ,  A61K31/513 ,  A61K31/515 ,  A61K31/53 ,  A61K31/55 ,  A61K31/5513 ,  A61K31/5517 ,  A61K31/57 ,  A61K31/7048 ,  A61K45/06 ,  A61K31/437 ,  A61K2300/00 ,  A61K31/57 ,  A61K2300/00 ,  A61K31/5517 ,  A61K2300/00 ,  A61K31/5513 ,  A61K2300/00 ,  A61K31/44 ,  A61K31/04 ,  A61K2300/00 ,  A61K2300/00 ,  A61K31/27 ,  A61K2300/00 ,  A61K31/433 ,  A61K2300/00 ,  A61K31/55 ,  A61K2300/00 ,  A61K31/4015 ,  A61K2300/00 ,  A61K31/195 ,  A61K2300/00 ,  A61K31/165 ,  A61K2300/00 ,  A61K31/53 ,  A61K2300/00 ,  A61K31/444 ,  A61K2300/00 ,  A61K31/515 ,  A61K2300/00 ,  A61K31/4166 ,  A61K2300/00 ,  A61K31/4192 ,  A61K2300/00 ,  A61K31/19 ,  A61K2300/00 ,  A61K31/513 ,  A61K2300/00 ,  A61K31/36 ,  A61K2300/00 ,  A61K31/4535 ,  A61K2300/00 ,  A61K31/7048 ,  A61K2300/00 ,  A61K31/197 ,  A61K2300/00 ,  A61K31/423 ,  A61K2300/00 ,  A61K31/136 ,  A61K2300/00

摘要： Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof.

公开(公告)号：US12104186B2

公开(公告)日：2024-10-01

申请号：US17199484

申请日：2021-03-12

申请人： TRUSTEES OF DARTMOUTH COLLEGE ,  STEALTH BIOLOGICS, LLC

发明人： Karl E. Griswold ,  Chris Bailey-Kellogg ,  Yoonjoo Choi ,  Kristina Blazanovic ,  Hongliang Zhao ,  Deeptak Verma

IPC分类号： C12N9/52 ,  A61K31/18 ,  A61K31/397 ,  A61K31/47 ,  A61K31/519 ,  A61K31/545 ,  A61K31/7036 ,  A61K31/7048 ,  A61K38/48 ,  A61K45/06 ,  A61K38/00

CPC分类号： C12N9/52 ,  A61K31/18 ,  A61K31/397 ,  A61K31/47 ,  A61K31/519 ,  A61K31/545 ,  A61K31/7036 ,  A61K31/7048 ,  A61K38/48 ,  A61K38/4886 ,  A61K45/06 ,  C12Y304/24075 ,  A61K38/00 ,  A61K38/48 ,  A61K2300/00 ,  A61K31/18 ,  A61K2300/00 ,  A61K31/397 ,  A61K2300/00 ,  A61K31/47 ,  A61K2300/00 ,  A61K31/519 ,  A61K2300/00 ,  A61K31/545 ,  A61K2300/00 ,  A61K31/7036 ,  A61K2300/00 ,  A61K31/7048 ,  A61K2300/00

摘要： Compositions comprising deimmunized lysostaphin and methods of using the same, e.g., to treat microbial infection in or on a subject, are provided.

公开(公告)号：US20240316133A1

公开(公告)日：2024-09-26

申请号：US18635597

申请日：2024-04-15

申请人： Ecofibre USA Inc.

发明人： Alexandra M. Capano ,  Pradeep Singh Tanwar ,  Alex Nance

IPC分类号： A61K36/185 ,  A61K31/01 ,  A61K31/015 ,  A61K31/045 ,  A61K31/05 ,  A61K31/198 ,  A61K31/216 ,  A61K31/282 ,  A61K31/337 ,  A61K31/352 ,  A61K31/355 ,  A61K31/395 ,  A61K31/4745 ,  A61K31/513 ,  A61K31/519 ,  A61K31/675 ,  A61K31/704 ,  A61K31/7048 ,  A61K31/7068 ,  A61K33/243 ,  A61K39/395 ,  A61P35/00

CPC分类号： A61K36/185 ,  A61K31/01 ,  A61K31/015 ,  A61K31/045 ,  A61K31/05 ,  A61K31/198 ,  A61K31/216 ,  A61K31/282 ,  A61K31/337 ,  A61K31/352 ,  A61K31/355 ,  A61K31/4745 ,  A61K31/513 ,  A61K31/519 ,  A61K31/5545 ,  A61K31/675 ,  A61K31/704 ,  A61K31/7048 ,  A61K31/7068 ,  A61K33/243 ,  A61K39/3955 ,  A61P35/00

摘要： Methods for treating ovarian cancer comprising: administering to a patient and effective amount of a cannabis extract comprising CBD wherein preferably the cannabis extract is administered via a mucosal formulation.

公开(公告)号：US20240316086A1

公开(公告)日：2024-09-26

申请号：US18425427

申请日：2024-01-29

申请人： LUNELLA BIOTECH, INC.

发明人： Michael P. LISANTI ,  Federica SOTGIA

IPC分类号： A61K31/7048 ,  A61K31/05 ,  A61K31/166 ,  A61K31/375 ,  A61K31/65 ,  A61K31/7052 ,  A61K47/54 ,  C07F9/54

CPC分类号： A61K31/7048 ,  A61K31/05 ,  A61K31/166 ,  A61K31/375 ,  A61K31/65 ,  A61K31/7052 ,  A61K47/542 ,  C07F9/5442

摘要： The present approach effectively eradicates senescent cells and cells carrying the hallmarks associated with aging, through inhibiting mitochondrial biogenesis during induced mitochondrial oxidative stress, without inhibiting normal cells. Embodiments may include a therapeutic agent that inhibits mitochondrial biogenesis and targets the large mitochondrial ribosome, a therapeutic agent that inhibits mitochondrial biogenesis and targets the small mitochondrial ribosome, and a therapeutic agent that behaves as a pro-oxidant or induces mitochondrial oxidative stress. Some embodiments include sub-antimicrobial antibiotic concentrations, thereby minimizing antibiotic resistance concerns.

公开(公告)号：US12097208B2

公开(公告)日：2024-09-24

申请号：US17459373

申请日：2021-08-27

申请人： OTICARA, INC.

发明人： Patrick Slater

IPC分类号： A61K31/573 ,  A61K9/00 ,  A61K9/06 ,  A61K31/137 ,  A61K31/27 ,  A61K31/4164 ,  A61K31/4174 ,  A61K31/4196 ,  A61K31/4418 ,  A61K31/496 ,  A61K31/506 ,  A61K31/7048 ,  A61P11/02 ,  A61P31/00

CPC分类号： A61K31/573 ,  A61K9/0043 ,  A61K9/06 ,  A61K31/137 ,  A61K31/27 ,  A61K31/4164 ,  A61K31/4174 ,  A61K31/4196 ,  A61K31/4418 ,  A61K31/496 ,  A61K31/506 ,  A61K31/7048 ,  A61P11/02 ,  A61P31/00

摘要： Compositions and methods are provided for treating diseases and conditions of the nasal, sinonasal and nasopharyngeal tissues.

公开(公告)号：US20240307628A1

公开(公告)日：2024-09-19

申请号：US18594627

申请日：2024-03-04

申请人： Boehringer Ingelheim Vetmedica GmbH

发明人： Claudius WEILER ,  Stefan Johannes LEHNER

IPC分类号： A61M5/315 ,  A61K31/7048

CPC分类号： A61M5/31513 ,  A61K31/7048

摘要： Systems and methods are described for treatment and/or prevention of a metabolic disorder and/or another medical condition in a patient (e.g., a feline) by administering to the patient a liquid pharmaceutical composition, preferably including one or more SGLT-2 inhibitor compound(s), via a delivery system that includes a syringe. The syringe includes features that facilitate easy, safe and effective doses of small volumetric amounts of the liquid pharmaceutical composition to the patient during administration.

公开(公告)号：US20240307426A1

公开(公告)日：2024-09-19

申请号：US18578207

申请日：2022-07-26

申请人： BOEHRINGER INGELHEIM VETMEDICA GMBH

发明人： Carla KROH ,  Ingo Ulrich LANG ,  José MATALLO

IPC分类号： A61K31/7056 ,  A61K31/382 ,  A61K31/7034 ,  A61K31/7048 ,  A61P13/12

CPC分类号： A61K31/7056 ,  A61K31/382 ,  A61K31/7034 ,  A61K31/7048 ,  A61P13/12

摘要： The present invention is directed to the use of one or more SGLT-2 inhibitors or pharmaceutically acceptable forms thereof for the prophylaxis and/or treatment of one or more renal diseases in a non-human mammal, such as a carnivore, in particular a cat or a dog.